SERPINH1 promoted the proliferation and metastasis of colorectal cancer by activating PI3K/Akt/mTOR signaling pathway

BACKGROUND Serpin peptidase inhibitor clade H member 1(SERPINH1)was initially recognized as an oncogene implicated in various human malignancies.Nevertheless,the clinical relevance and functional implications of SERPINH1 in colorectal cancer(CRC)remain largely elusive.AIM To investigate the effects of SERPINH1 on CRC cells and its specific mechanism.METHODS Quantitative real-time polymerase chain reaction,western blotting analysis,The Cancer Genome Atlas data mining and immunohistochemistry were employed to examine SERPINH1 expression in CRC cell lines and tissues.A series of in-vitro assays were performed to demonstrate the function of SERPINH1 and its possible mechanisms in CRC.RESULTS SERPINH1 demonstrated elevated expression levels in both CRC cells and tissues,manifested at both mRNA and protein tiers.Elevated SERPINH1 levels correlated closely with advanced T stage,lymph node involvement,and distant metastasis,exhibiting a significant association with poorer overall survival among CRC patients.Subsequent investigations unveiled that SERPINH1 overexpression notably bolstered CRC cell proliferation,invasion,and migration in vitro,while conversely,SERPINH1 knockdown elicited the opposite effects.Gene set enrichment analysis underscored a correlation between SERPINH1 upregulation and genes associated with cell cycle regulation.Our findings underscored the capacity of heightened SERPINH1 levels to expedite G1/S phase cell cycle progression via phosphatidylinositol 3-kinase/AKT/mechanistic target of rapamycin pathway activation,thereby facilitating CRC cell invasion and migration.CONCLUSION These findings imply a crucial involvement of SERPINH1 in the advancement and escalation of CRC,potentially positioning it as a novel candidate for prognostic assessment and therapeutic intervention in CRC management.

MiR-451 inhibits proliferation of esophageal carcinoma cellline EC9706 by targeting CDKN2D and MAP3K1

AIM To investigate the underlying molecularmechanisms of miR-451 to inhibit proliferation ofesophageal carcinoma cell line EC9706.METHODS： Assays for cell growth, apoptosis andinvasion were used to evaluate the effects of miR-451expression on EC cells. Luciferase reporter and Westernblot assays were used to test whether cyclin-dependentkinase inhibitor 2D （CDKN2D） and MAP3K1 act as majortargets of miR-451.RESULTS： The results showed that CDKN2D andMAP3K1 are direct targets of miR-451. CDKN2D andMAP3K1 overexpression reversed the effect of miR-451.MiR-451 inhibited the proliferation of EC9706 bytargeting CDKN2D and MAP3K1.CONCLUSION： These findings suggest that miR-451might be a novel prognostic biomarker and a potentialtarget for the treatment of esophageal squamous cellcarcinoma in the future.

Inhibitory Effect of Histone Deacetylase Inhibitor on the Proliferation of Leukemia Cells and Its Anti-Tumor Pharmacology

The aim of this study was to explore the inhibitory effect of histone deacetylase inhibitor (HDACI) on the proliferation of leukemia cells. The two kinds of leukemia cells (human promyelocytic leukemia cell (HL-60) and human acute myelogenous leukemia cell (KG-1)) were selected for in vitro research. Besides, Chidamide, a kind of benzamide HDACI, was applied to induce and culture the HL-60 and KG-1 cells, and the anti-tumor cell proliferation activity of Chidamide on HL-60 and KG-1 was detected by the methyl thiazolyl tetrazolium (MTT) assay, which was 5.6 and 6.1 in turn. The cell scratch experiment verified that Chidamide had the metastasis inhibitory effect on HL-60 and KG-1 cells. Flow cytometry was employed to measure the percentage of apoptotic cells, and it was found that the percentage of apoptotic cells was 55.6% ± 1% and 48.6% ± 1% in sequence after HL-60 and KG-1 cells were treated with Chidamide for 36 hours. The number of auto-phagosomes was determined by transmission electron microscopy showing that the number of auto-phagosomes in HL-60 and KG-1 cells was 12 ± 1 and 10 ± 1, respectively after the induction process of Chidamide. The phosphorylated histone H2AX protein (γ-H2AX) recognition antibody immunofluorescence method was adopted to determine the deoxyribonucleic acid (DNA) damage, and the positive rates of HL-60 and KG-1 cells reached 28.41% and 26.35%, respectively after Chidamide treatment. Therefore, Chidamide, as a kind of HDACI, could effectively inhibit the proliferation of leukemia cells, so that the results of this experiment had a good guiding meaning for the clinical diagnosis and treatment of leukemia.

EFFECTS OF BLEOMYCIN A5 COMBINED WITH CALMODU-LIN INHIBITOR ON THE PROLIFERATION OF S-180 CELLS IN VITRO

The effects of bleomycin A5 (BLM A5) alone and combined with calmodulin inhibitor N-(4-aminobutyl)-5-chloro-2-naphthalene sulfonamide (W-13) on the proliferation on S-180 cells in vitro were studied. IC50 of BLM used alone for the cells was about 2.63 μg/ml, but it was reduced to 1/3.8 and 1/9.5 of 2.63 μg/ml when plus W-13 1, 5 μg/ml respectively. The results indicated that nontoxic doses of W-13 enhanced the hinibition of cell proliferation under the condition of BLM 0.5 - 2.5 μg/ ml. In colony forming test, the survival fraction of S-180 cells treated with BLM plus W-13 was decreased to 1/87 - 240 of that of the cells treated with BLM alone. The results suggest that W-13 can enhance antitumor activity of BLM in vitro and may be used as an synergist of BLM A5 in vivo.

山甲白花汤联合吉西他滨抗胰腺癌耐药机制研究

目的:探讨山甲白花汤联合吉西他滨抗胰腺癌耐药的作用机制。方法:将30只小鼠按随机数表法分为模型组、吉西他滨组和联合组,构建皮下移植瘤小鼠模型,分别使用山甲白花汤、吉西他滨及联合处理小鼠,观察肿瘤的体积、重量变化和类固醇受体辅激活因子/分化抑制蛋白1(Src/Id1)信号通路蛋白。将人胰腺癌细胞系1(PANC-1)细胞分为对照组、吉西他滨处理组、联合处理组、联合+微小核糖核酸-124-3p抑制剂(miR-124-3p inhibitor)组和联合+过表达信号转导蛋白2样1(oe-SDF2L1)组,比较各组细胞增殖与迁移能力、微核糖核酸-124-3p(miR-124-3p)、信号转导蛋白2样1(SDF2L1)及信使核糖核酸(mRNA)水平。结果:与吉西他滨组比较,联合组中肿瘤体积与重量降低、Id1和磷酸化非受体酪氨酸激酶/非受体酪氨酸激酶(p-Src/Src)、SDF2L1水平降低。与对照组比较,吉西他滨处理组细胞增殖与迁移率明显降低,微小核糖核酸-124-3p(miR-124-3p)水平升高且SDF2L1水平明显降低,与吉西他滨处理组比较,联合处理组细胞增殖与迁移率明显降低,miR-124-3p水平升高且SDF2L1水平明显降低,与联合处理组比较,联合+miR-124-3p inhibitor组和联合+oe-SDF2L1组细胞增殖与迁移率均明显升高,SDF2L1水平均明显升高。结论:山甲白花汤联合吉西他滨通过上调miR-124-3p抑制SDF2L1发挥抗胰腺癌耐药作用。

STAT3抑制剂stattic对小鼠结肠癌CT26细胞增殖和凋亡的影响

目的探讨信号转导和转录激活因子3(STAT3)抑制剂盐酸萘替芬(stattic)对小鼠结肠癌CT26细胞增殖和凋亡的影响和作用机制。方法采用0μmol/L、1μmol/L、5μmol/L、10μmol/L stattic溶液处理小鼠结肠癌CT26细胞,通过CCK-8实验、细胞克隆形成实验、细胞划痕实验、Transwell侵袭实验以及流式细胞术检测细胞活力、增殖、迁移、侵袭、周期和凋亡情况;利用Western blot法检测stattic对小鼠结肠癌细胞磷酸化STAT3(p-STAT3)表达的影响;通过实时荧光定量多聚核苷酶链式反应(RT-qPCR)检测stattic作用后CT26细胞B淋巴细胞瘤-2(Bcl-2)和人跨膜受体蛋白Notch-1(Notch-1)的表达。结果与0μmol/L组相比,stattic溶液组CT26细胞的活力及增殖能力降低(P<0.001)、迁移率和侵袭率降低(P<0.001),细胞凋亡率随浓度增加而增加(P<0.0001);stattic能将CT26细胞周期阻断于G1期,进而阻止CT26细胞的增殖;Western blot结果显示stattic抑制CT26细胞p-STAT3的表达(P<0.05);RT-qPCR检测结果表明stattic下调CT26细胞Bcl-2和Notch1的表达(P<0.05)。结论stattic通过阻断STAT3信号,抑制p-STAT3蛋白的表达,下调下游抗凋亡分子Bcl-2和Notch1信号分子的表达从而抑制CT26细胞增殖促进细胞凋亡。

血清sMICA、PCNA、GASP-1、TIMP-1在非小细胞肺癌患者中的表达及相关性分析

目的探讨血清可溶性MHC-I类链相关蛋白A(sMICA)、增殖细胞核抗原(PCNA)、G蛋白偶联受体相关分选蛋白1(GASP-1)、组织金属蛋白酶抑制剂1(TIMP-1)在非小细胞肺癌(NSCLC)患者中的表达及与病理分型的相关性。方法2020年7月至2022年8月诊治的86例NSCLC患者作为研究对象,并设立为观察组,同期选取43例健康体检者设立为对照组;并根据不同病理分型将观察组分为腺癌组(n=33)和鳞癌组(n=53),对比血清sMICA、PCNA、GASP-1、TIMP-1;并采用Logistic回归模型分析sMICA、PCNA、GASP-1、TIMP-1对非小细胞肺癌的影响;采用ROC曲线模型分析sMICA、PCNA、GASP-1、TIMP-1诊断非小细胞肺癌的AUC、敏感度及特异度。结果观察组的sMICA、PCNA、GASP-1、TIMP-1均高于对照组(P<0.05)。腺癌组的sMICA、PCNA、GASP-1、TIMP-1均高于鳞癌组(P<0.05)。二元Logistic回归模型分析显示,sMICA、PCNA、GASP-1、TIMP-1高表达会对非小细胞肺癌的发生产生影响(P<0.05)。ROC曲线分析显示,sMICA、PCNA、GASP-1、TIMP-1及四项联合诊断NSCLC的AUC值分别为(0.750、0.654、0.819、0.788、0.843,P均<0.05),敏感度分别为57.00%、46.50%、67.40%、90.70%、79.10%;特异度分别为93.00%、93.00%、88.40%、58.10%、86.00%。结论sMICA、PCNA、GASP-1、TIMP-1在NSCLC患者中呈高表达趋势,其表达水平会随病理分型而升高。

牛膝含药血清对大鼠骨髓间充质干细胞增殖和成骨分化的影响及其作用机制

目的:探讨牛膝含药血清对大鼠骨髓间充质干细胞(bone marrow mesenchymal stem cells, BMSCs)增殖、成骨分化的影响及其作用机制。方法:取4周龄雌性SPF级SD大鼠20只,随机分为空白组和牛膝低、中、高剂量组,每组5只。牛膝低、中、高剂量组大鼠分别以相应浓度的牛膝药液灌胃,空白组大鼠以同等剂量生理盐水灌胃,每日1次,共灌胃14 d。最后一次灌胃干预2 h后,取大鼠腹主动脉血,制备空白血清和相应浓度的牛膝含药血清。另取大鼠4只,处死后取出大鼠股骨和胫骨骨髓,进行BMSCs培养。细胞传到第3代时,用流式细胞仪进行细胞表型鉴定。将大鼠BMSCs分为胎牛血清组、空白血清组和牛膝含药血清低、中、高剂量组,分别加入胎牛血清、空白血清和牛膝低、中、高剂量含药血清进行干预,检测各组大鼠BMSCs的增殖活性;分别加入含相应血清的成骨诱导液进行成骨诱导,采用茜素红染色观察大鼠BMSCs成骨分化情况,采用荧光定量PCR检测大鼠BMSCs中成骨相关因子碱性磷酸酶(alkaline phosphatase, ALP)、骨钙素(osteocalcin, OCN)、Runt相关转录因子2(runt-related transcription factor 2,Runx2)和Osterix的mRNA相对表达量,采用蛋白质印迹法检测BMSCs中Hedgehog信号通路相关蛋白音猬因子(sonic hedgehog, SHH)、Gli2的蛋白相对表达量。结果:①细胞鉴定结果。细胞表型鉴定结果显示,培养的细胞为BMSCs。②大鼠BMSCs增殖活性检测结果。干预24 h、48 h、72 h、96 h后,5组大鼠BMSCs增殖活性组间总体比较,差异均有统计学意义;干预24 h后,牛膝含药血清高剂量组BMSCs的增殖活性高于胎牛血清组、空白血清组(P=0.006,P=0.008);干预48 h、72 h、96 h后,牛膝含药血清高剂量组BMSCs的增殖活性均高于胎牛血清组、空白血清组和牛膝含药血清低、中剂量组(P=0.000,P=0.000,P=0.010,P=0.021;P=0.003,P=0.000,P=0.007,P=0.016;P=0.000,P=0.000,P=0.002,P=0.047)。③大鼠BMSCs成骨分化检测结果。茜素红染色显示,各组大鼠BMSCs均出现细胞外矿化结节形成与沉积,其中牛膝含药血清高剂量组阳性染色面积较大,矿化结节明显。牛膝含药血清高剂量组矿化结节面积大于胎牛血清组和空白血清组(P=0.039,P=0.015)。④大鼠BMSCs中成骨相关因子的mRNA相对表达量检测结果。牛膝含药血清低、中、高剂量组大鼠BMSCs中ALP、OCN、Runx2、Osterix的mRNA相对表达量均高于胎牛血清组(P=0.003,P=0.000,P=0.000;P=0.011,P=0.001,P=0.000;P=0.009,P=0.000,P=0.000;P=0.000,P=0.000,P=0.000)和空白血清组(P=0.000,P=0.000,P=0.000;P=0.005,P=0.000,P=0.000;P=0.031,P=0.001,P=0.000;P=0.000,P=0.000,P=0.000)。牛膝含药血清中剂量组大鼠BMSCs中ALP的mRNA相对表达量高于牛膝含药血清低剂量组(P=0.044)。牛膝含药血清高剂量组大鼠BMSCs中ALP、OCN、Runx2、Osterix的mRNA相对表达量均高于牛膝含药血清低剂量组(P=0.002,P=0.006,P=0.002,P=0.008)。牛膝含药血清高剂量组大鼠BMSCs中Runx2的mRNA相对表达量高于牛膝含药血清中剂量组(P=0.047)。⑤大鼠BMSCs中Hedgehog信号通路相关蛋白的蛋白相对表达量检测结果。牛膝含药血清高剂量组大鼠BMSCs中SHH、Gli2高表达。牛膝含药血清低、中、高剂量组SHH、Gli2的蛋白相对表达量均高于胎牛血清组(P=0.000,P=0.000,P=0.000;P=0.026,P=0.016,P=0.000)和空白血清组(P=0.000,P=0.000,P=0.000;P=0.031,P=0.018,P=0.000)。牛膝含药血清中、高剂量组大鼠BMSCs中SHH的蛋白相对表达量均高于牛膝含药血清低剂量组(P=0.000,P=0.000),牛膝含药血清高剂量组大鼠BMSCs中SHH的蛋白相对表达量高于牛膝含药血清中剂量组(P=0.000)。牛膝含药血清高剂量组大鼠BMSCs中Gli2的蛋白相对表达量高于牛膝含药血清低剂量组(P=0.001)。结论:牛膝含药血清可能通过激活Hedgehog信号通路和上调成骨相关因子ALP、OCN、Runx2、Osterix的表达,促进大鼠BMSCs的增殖和成骨分化。

Effect of cis-9,trans-11-conjugated linoleic acid on cell cycle of gastric adenocarcinoma cell line(SGC-7901)

AIM: To determine the effect of cis -9, trans -11-conjugated linoleic acid (c9, t11-CLA) on the cell cycle of gastric cancer cells (SGC-7901) and its possible mechanism in inhibition cancer growth. METHODS: Using cell culture and immunocytochemical techniques, we examined the cell growth, DNA synthesis, expression of PCNA, cyclin A, B(1), D(1), p16(ink4a) and p21(cip/waf1) of SGC-7901 cells which were treated with various c9, t11-CLA concentrations (25, 50, 100 and 200 micromol.L(-1))of c 9, t 11-CLA for 24 and 48h, with a negative control (0.1% ethane). RESULTS: The cell growth and DNA synthesis of SGC-7901 cells were inhibited by c9, t11-CLA.SGC-7901 cells. Eight day after treatment with various concentrations of c9, t11-CLA mentioned above, the inhibition rates were 5.92%, 20.15%, 75.61% and 82.44%, respectively and inhibitory effect of c9, t11-CLA on DNA synthesis (except for 25 micromol.L, 24h) showed significantly less (3)H-TdR incorporation than that in the negative controls (P【0.05 and P【0.01). Immunocytochemical staining demonstrated that SGC-7901 cells preincubated in media supplemented with different c9, t11-CLA concentrations at various times significantly decreased the expressions of PCNA (the expression rates were 7.2-3.0%, 24h and 9.1-0.9% at 48h, respectively), Cyclin A (11.0-2.3%, 24h and 8.5-0.5%,48h), B(1) (4.8-1.8% at 24h and 5.5-0.6% at 48h)and D(1) (3.6-1.4% at 24h and 3.7%-0 at 48h) as compared with those in the negative controls(the expressions of PCNA, Cyclin A, B(1) and D(1) were 6.5% at 24h and 9.0% at 48h, 4.2% at 24h and 5.1% at 48h, 9.5% at 24h and 6.0% at 48h,respectively)(P【0.01), whereas the expressions of P16(ink4a) and P21(cip/waf1), cyclin-dependent kinases inhibitors(CDKI), were increased. CONCLUSION: The cell growth and proliferation of SGC-7901 cell is inhibited by c9, t11-CLA via blocking the cell cycle, with reduced expressions of cyclin A,B(1) and D(1) and enhanced expressions of CDKI(P16(ink4a) and p21(cip/waf1)).

Bowman-Birk inhibitors from legumes as colorectal chemopreventive agents

Aberrant functioning of serine proteases in inflammatory and carcinogenic processes within the gastrointestinal tract(GIT)has prompted scientists to investigate the potential of serine protease inhibitors,both natural and synthetic,as modulators of their proteolytic activities.Protease inhibitors of the Bowman-Birk type,a major protease inhibitor family in legume seeds,which inhibit potently and specifically trypsin-and chymotrypsin-like proteases,are currently being investigated as colorectal chemopreventive agents.Physiologically relevant amounts of Bowman-Birk inhibitors(BBI)can reach the large intestine in active form due to their extraordinary resistance to extreme conditions within the GIT.Studies in animal models have proven that dietary BBI from several legume sources,including soybean,pea,lentil and chickpea,can prevent or suppress carcinogenic and inflammatory processes within the GIT.Although the therapeutic targets and the action mechanism of BBI have not yet been elucidated,the emerging evidence suggests that BBI exert their preventive properties via protease inhibition;in this sense,serine proteases should be considered as primary targets in early stages of carcinogenesis.The validation of candidate serine proteases as therapeutic targets together with the identification,within the wide array of natural BBI variants,of the most potent and specific protease inhibitors,are necessary to better understand the potential of this protein family as colorectal chemopreventive agents.

The cancer-testis gene,MEIOB,sensitizes triple-negative breast cancer to PARP1 inhibitors by inducing homologous recombination deficiency

Objective:The newly defined cancer-testis(CT)gene,MEIOB,was previously found to play key roles in DNA double-strand break(DSB)repair.In this study,we aimed to investigate the effects and mechanisms of MEIOB in the carcinogenesis of triple-negative breast cancers(TNBCs).Methods:The Cancer Genome Atlas database was used to quantify the expression of MEIOB.Cox regression analysis was used to evaluate the association between MEIOB expression and the prognosis of human TNBC.The effects of MEIOB on cell proliferation and migration in TNBCs were also assessed in vitro.Patient-derived xenograft(PDX)models were used to assess the sensitivity of breast cancers with active MEIOB to PARP1 inhibitors.Results:We confirmed MEIOB as a CT gene whose expression was restricted to the testes and breast tumors,especially TNBCs.Its activation was significantly associated with poor survival in breast cancer patients[overall,hazard ratio(HR)=1.90(1.16–2.06);TNBCs:HR=7.05(1.16–41.80)].In addition,we found that MEIOB was oncogenic and significantly promoted the proliferation of TNBC cells.Further analysis showed that MEIOB participated in DSB repair in TNBCs.However,in contrast to its function in meiosis,it mediated homologous recombination deficiency(HRD)through the activation of poly ADP-ribose polymerase(PARP)1 by interacting with YBX1.Furthermore,activated MEIOB was shown to confer sensitivity to PARP inhibitors,which was confirmed in PDX models.Conclusions:MEIOB played an oncogenic role in TNBC through its involvement in HRD.In addition,dysregulation of MEIOB sensitized TNBC cells to PARP inhibitors,so MEIOB may be a therapeutic target of PARP1 inhibitors in TNBC.

Circadian variation in expression of G_1 phase cyclins D_1 and E and cyclin-dependent kinase inhibitors p16 and p21 in human bowel mucosa

AIM： To evaluate whether the cellular proliferation rate in the large bowel epithelial cells is characterized by circadian rhythm. METHODS： Between January 2003 and December 2004, twenty patients who were diagnosed as suffering from primary, resectable, non-metastatic adenocarcinoma of the lower rectum, infiltrating the sphincter mechanism, underwent abdominoperineal resection, total mesorectal excision and permanent left iliac colostomy. In formalinfixed and paraffin-embedded biopsy specimens obtained from the colostomy mucosa every six hours （00：00, 06：00, 12：00, 18：00 and 24：00）, we studied the expression of G1 phase cyclins （D1 and E） as well as the expression of the G1 phase cyclin-dependent kinase （CDK） inhibitors p16 and p21 as indicators of cell cycle progres- sion in colonic epithelial cells using immunohistochemical methods. RESULTS： The expression of both cyclins showed a similar circadian fashion obtaining their lowest and highest values at 00：00 and 18：00, respectively （P〈 0.001）. A circadian rhythm in the expression of CDK inhibitor proteins p16 and p21 was also observed, with the lowest levels obtained at 12：00 and 18：00 （P〈0.001）, respectively. When the complexes cyclins D1-p21 and E-p21 were examined, the expression of the cyclins was adversely correlated to the p21 expression throughout the day. When the complexes the cyclins D1-p16 and E-p16 were examined, high levels of p16 expression were correlated to low levels of cyclin expression at 00：00, 06：00 and 24：00. Meanwhile, the highest expression levels of both cyclins were correlated to high levels of p16 expression at 18：00. CONCLUSION： Colonic epithelial cells seem to enter the G1 phase of the cell cycle during afternoon （between 12：00 and 18：00） with the highest rates obtained at 18：00. From a clinical point of view, the present results suggest that G1-phase specific anticancer therapies in afternoon might maximize their anti-tumor effect while minimizing toxicity.

端粒酶抑制因子X1过表达对人食管癌EC1细胞增殖及凋亡的影响

目的探究端粒酶抑制因子X1(PinX1)对人食管癌EC1细胞增殖及凋亡的影响。方法体外培养人食管癌细胞系EC1细胞株,并将其分为空白对照(NG)组(空白对照细胞)、pcDNA组(转染阴性对照质粒)、pcDNA-PinX1组(转染PinX1过表达质粒)、N-乙酰-L-半胱氨酸(NAC)组(加入信号通路抑制剂)。采用实时荧光定量PCR法检测各组PinX1 mRNA的表达水平。分别采用CCK-8法和流式细胞术检测各组细胞的增殖、凋亡情况。采用荧光探针法检测各组活性氧簇(ROS)水平。采用蛋白质印迹法检测各组腺苷酸激活蛋白激酶/信号转导与转录激活因子3(AMPK/STAT3)信号通路相关蛋白的表达水平。结果经成功转染细胞后,与NG组、pcDNA组比较,pcDNA-PinX1组细胞的增殖抑制率、凋亡率、ROS水平、p-AMPK/AMPK均升高,而p-STAT3/STAT3均降低,差异均有统计学意义(P均<0.05)。与pcDNA-PinX1组比较,NAC组细胞的增殖抑制率、凋亡率、ROS水平、p-AMPK/AMPK均降低,p-STAT3/STAT3升高,差异均有统计学意义(P均<0.05)。结论PinX1过表达可抑制人食管癌EC1细胞增殖并诱导其凋亡,可能通过促进ROS/AMPK/STAT3信号通路活化来实现。

Assessment of the tumor malignancy after immunotherapy combined with EGFR-TKIs drug treatment of EGFR-mutant advanced non-small cell lung cancer

Objective:To study the effect of immunotherapy combined with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) drug therapy on the tumor malignancy in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC).Methods:Patients with EGFR-mutant advanced NSCLC who were treated in Xi'an No.1 Hospital and Shaanxi Provincial Tumor Hospital between May 2014 and August 2015 were selected as the research subjects and randomly divided into DC-CIK group and control group, the former received immunotherapy combined with EGFR-TKI drug therapy, and the latter received EGFR-TKI drug therapy. Before and after treatment, the cancer cell viability-related marker levels in serum as well as the antitumor immune response marker molecule expression in peripheral blood mononuclear cells were determined respectively, and the proliferation-related gene expression in lung cancer lesions were determined after treatment.Results: 2 weeks and 4 weeks after treatment, serum CEA, Cyfra21-1 and SCCA levels of both groups were significantly lower than those before treatment and serum CEA, Cyfra21-1 and SCCA levels of DC-CIK group were significantly lower than those of control group, CD3, CD4 and CD8 fluorescence intensity in peripheral blood mononuclear cells of DC-CIK group were significantly higher than those before treatment, and the CD3, CD4 and CD8 fluorescence intensity in peripheral blood mononuclear cells of control group were not significantly different from those before treatment;TCF3, MEF2D and cFLIP(L) expression in lung cancer lesions of DC-CIK group were significantly lower than those of control group while FRMD8, PDCD5, caspase-3 and caspase-8 expression were significantly higher than those of control group.Conclusion:Immunotherapy combined with EGFR-TKI drug treatment of EGFR-mutant advanced non-small cell lung cancer (NSCLC) can enhance the antitumor immune response and promote cancer cell apoptosis.

丝氨酸肽酶抑制因子Kazal型1对肝癌细胞增殖的影响及其机制

目的探讨丝氨酸肽酶抑制因子Kazal型1(SPINK1)对肝癌细胞RH-35增殖的影响及其分子机制。方法利用基因表达综合(GEO)数据库分析Spink1基因在肝癌患者和大鼠肝癌模型中的表达,用重组大鼠SPINK1蛋白(rrSPINK1)处理RH-35细胞,采用MTT、流式细胞术、5-乙炔基-2’-脱氧尿苷(EdU)等方法检测SPINK1对RH-35细胞增殖的影响,Real-time PCR和Western blotting检测SPINK1信号通路、细胞增殖和凋亡相关基因的表达。结果SPINK1在肝癌和大鼠肝癌模型中显著高表达;与对照组相比,rrSPINK1处理的RH-35细胞活力,EdU阳性细胞率,S期和G_2/M期细胞比例明显增加;而RH-35细胞凋亡无显著变化;rrSPINK1上调RH-35细胞中p38 MAPK和STAT信号通路相关基因/蛋白的表达;并且在肝癌中Spink1基因的表达与Mapk13、Stat1和Stat3基因正相关。结论SPINK1促进肝癌细胞中p38 MAPK和Janus激酶/信号转导及转录激活因子(JAK/STAT)的表达,促进肝癌细胞的增殖。

STAT3抑制剂S3I-201对人肝癌BEL-7402细胞增殖、凋亡及细胞周期的影响

目的 研究STAT3小分子抑制剂S3I-201对人肝癌细胞系BEL-7402增殖、凋亡与细胞周期的影响和初步的作用机制。方法 分别采用细胞活性检测试剂盒cell couting kit-8(CCK-8)和EdU细胞增殖法检测S3I-201对人肝癌细胞BEL-7402细胞增殖的影响,应用流式细胞术分析S3I-201对BEL-7402的细胞凋亡和周期的影响,通过Western blotting检测凋亡相关蛋白Bcl-2、Bax的表达。结果 CCK-8及EdU结果显示,S3I-201能抑制BEL-7402细胞的生长和增殖(P<0.05),使BEL-7402细胞阻滞于S期,具有诱导细胞凋亡的作用,上调Bax的表达,下调Bcl-2的表达(P<0.05)。结论 STAT3小分子抑制剂S3I-201通过促进BEL-7402凋亡、上调促凋亡蛋白Bax、下调抗凋亡蛋白Bcl-2的表达,并将BEL-7402阻滞于S期而发挥抗肿瘤效应。

复方藤梨汤含药血清对人脑胶质瘤U251细胞增殖、凋亡及上皮间质转化的影响

目的探究复方藤梨汤含药血清对人脑胶质瘤U251细胞增殖、凋亡及上皮间质转化的影响。方法将24只雄性SD大鼠分为对照组和低、中、高剂量组[复方藤梨汤6、12、24g/(kg·d)],每组6只,制备含药血清处理人脑胶质瘤U251细胞。采用CCK-8法检测细胞活力,集落形成实验检测细胞克隆形成能力,流式细胞术检测细胞周期分布与细胞凋亡,定量聚合酶链反应检测原癌基因C-myc、细胞周期蛋白D1(CyclinD1)基因表达,Western blot法检测细胞凋亡蛋白[B细胞淋巴瘤-2(Bcl-2)、Bcl-2相关X蛋白(Bax)、胱天蛋白酶(Caspase)-3、Caspase-8]以及β-连环蛋白(β-catenin)、上皮性黏附蛋白(E-cadherin)及波形蛋白(Vimentin)表达。结果选取体积分数10%的含药血清为最终剂量。与对照组比较,低、中、高剂量组细胞活力、克隆形成数、C-myc mRNA、CyclinD1 mRNA、Vimentin表达水平降低,处于S期细胞比例、Bax/Bcl-2比值、Caspase-3表达水平升高(P<0.05);低、高剂量组G1期细胞比例降低(P<0.05);中、高剂量组G2期细胞比例、β-catenin表达水平降低,Caspase-8和E-cadherin表达水平升高(P<0.05);高剂量组细胞凋亡率升高(P<0.05)。结论复方藤梨汤含药血清可促使人脑胶质瘤U251细胞阻滞于S期,抑制细胞增殖,诱导细胞凋亡,通过调节β-catenin、E-cadherin和Vimentin表达抑制上皮间质转化。

微小RNA-127-3p对乳头状甲状腺癌细胞增殖、侵袭及迁移的影响

目的 探讨微小RNA-127-3p(miR-127-3p)对乳头状甲状腺癌细胞增殖、侵袭及迁移的影响,并明确miR-127-3p与肿瘤细胞侵袭抑制因子(SCAI)基因的靶向关系。方法 选取乳头状甲状腺癌细胞株TPC1、正常人甲状腺细胞株Nthy-ori 3-1为研究对象。将生长良好的TPC1细胞株根据转染方式的不同分为空白组(NC组,未进行任何处理)、miR-NC组(转染miR-127-3p过表达的空载体)、miR-127-3p组(转染miR-127-3p-mimics)、si-NC组(转染SCAI敲低空载体)和si-SCAI组(转染si-SCAI)。采用噻唑蓝(MTT)实验检测细胞增殖能力,Transwell小室实验检测细胞迁移、侵袭能力,实时荧光定量聚合酶链反应(PCR)检测细胞中miR-127-3p、SCAI mRNA的表达水平,蛋白质印迹法(Western blot)检测细胞SCAI蛋白表达水平。采用生物信息预测miR-127-3p与SCAI的靶向作用关系,并使用荧光素酶报告实验进行验证。结果 TPC1细胞中的miR-127-3p表达水平低于Nthy-ori 3-1细胞,SCAI蛋白、SCAI mRNA表达水平高于Nthy-ori 3-1细胞,差异有统计学意义(P<0.01)。与NC组、miR-NC组比较,miR-127-3p组细胞48、72 h时的增殖能力、细胞迁移和侵袭能力降低,差异有统计学意义(P<0.01)。与NC组、si-NC组比较,si-SCAI组细胞48、72 h时的增殖能力、细胞迁移和侵袭能力升高,差异有统计学意义(P<0.01)。与NC组和miR-NC组比较,miR-127-3p组SCAI蛋白表达水平升高,差异有统计学意义(P<0.01)。转载WT-SCAI的miR-127-3p组细胞荧光素酶活性高于转载WT-SCAI的NC组细胞,差异有统计学意义(P<0.05)。结论 乳头状甲状腺癌细胞中的miR-127-3p、SCAI呈低表达,过表达miR-127-3p可能通过促进SCAI的表达抑制乳头状甲状腺癌细胞的增殖、侵袭和迁移。

MELK抑制剂OTSSP167抗弥漫性大B细胞淋巴瘤的实验研究

目的:探讨MELK抑制剂OTSSP167在抗弥漫性大B细胞淋巴瘤(DLBCL)中的作用。方法:采用CCK-8法检测OTSSP167对细胞生长活性的影响;EdU染色后流式检测OTSSP167对DLBCL细胞增殖能力的影响;Annexin V-FITC/PI双染色法检测OTSSP167对DLBCL细胞凋亡的影响;DLBCL细胞接种裸鼠后给予OTSSP167治疗,4周后检测OTSSP167对DLBCL体内生长的影响;Caspase-Glo^(TM)3/7酶活性试剂盒检测OTSSP167对DLBCL细胞Caspase 3/7酶活性的影响;Western blot检测凋亡和周期相关蛋白的表达水平。结果:OTSSP167显著抑制了SUDHL2、HBL1细胞的活性并呈一定的剂量依赖性(r=-0.61,r=-0.52);EdU染色后流式检测结果表明,OTSSP167能够显著抑制SUDHL2、HBL1细胞的增殖;Annexin V-FITC/PI结果显示,OTSSP167均能够显著促进SUDHL2、HBL1细胞的凋亡(P<0.001);体内实验结果表明,OTSSP167能够抑制SUDHL2细胞在裸鼠体内的生长,肿瘤组织TUNEL染色结果进一步证实OTSSP167能够促进SUDHL2细胞的凋亡;Caspase 3/7酶活性检测结果表明,OTSSP167均能够显著提高SUDHL2、HBL1细胞中Caspase活性(r=0.98,r=0.87);Western blot结果表明,OTSSP167能够剂量依赖性抑制凋亡信号通路中PARP、Bcl-xL、Bcl-2的表达(r=-0.93,r=-0.66,r=-0.87),而p53则显著上调(r=0.82),同时与细胞周期相关的蛋白cdc2、Cyclin E1、Cyclin A2及Cyclin B1也呈现剂量依赖性下调(r=-0.89,r=-0.83,r=-0.61,r=-0.93)。结论:MELK抑制剂OTSSP167能够通过抑制周期相关蛋白和抗凋亡相关蛋白的表达进而抑制DLBCL细胞增殖和促进DLBCL细胞的凋亡。

ANO1抑制剂在AngⅡ诱导的VSMC增殖中的作用研究

目的研究钙激活氯通道蛋白1(ANO1)抑制剂在血管紧张素Ⅱ(AngⅡ)诱导的血管平滑肌细胞(VSMC)增殖中的作用。方法研究时间为2019年7月至2022年6月。体外培养大鼠胸主动脉平滑肌细胞A7r5细胞株,AngⅡ刺激A7r5细胞建立细胞增殖模型,分别采用10 nmol/L、100 nmol/L、500 nmol/L不同浓度ANO1抑制剂(A01)干预,同时设置对照组(以等量生理盐水干预),采用Hoechst 33342荧光染色法观察ANO1抑制剂干预后AngⅡ诱导的VSMC形态学变化,蛋白免疫印迹法检测ANO1抑制剂干预后AngⅡ诱导的VSMC细胞凋亡相关蛋白表达水平。多组间比较采用单因素方差分析,组间两两比较采用LSD-t检验。结果Hoechst 33342荧光染色结果显示,随着ANO1抑制剂浓度增加,呈亮蓝色的细胞愈来愈多(染色质凝聚、出现凋亡小体),即细胞凋亡数量越多。低剂量组、中剂量组、高剂量组凋亡率分别为(17.60±1.36)%、(36.30±3.50)%、(61.25±6.33)%,均高于对照组凋亡率(4.32±0.51)%,组间差异均有统计学意义(均P<0.05),即AngⅡ诱导的VSMC增殖后凋亡与ANO1抑制剂浓度之间存在剂量依赖性。蛋白免疫印迹法检测ANO1抑制剂干预后AngⅡ诱导的VSMC凋亡相关蛋白结果显示,不同组间EPK、AKT、CDK4、Cyclin D1蛋白相对表达量主效应差异有统计学意义(P<0.05);与对照组比较,低剂量组、中剂量组、高剂量组EPK、AKT、CDK4、Cyclin D1蛋白相对表达量均降低,且呈剂量依赖性,各组间差异均有统计学意义(均P<0.05)。结论ANO1抑制剂可显著抑制AngⅡ诱导的VSMC增殖作用,其机制可能与抑制EPK/AKT信号通路及细胞周期进程有关。